Compositions and methods for diagnosis and treatment of metabolic syndrome
Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
1. A method of treatment of hyperferritinemia, comprising:
administering to a patient in need thereof, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more odd chain fatty acids or pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the hyperferritinemia is hyperferritinemia with iron overload.
3. The method of claim 1 , wherein the hyperferritinemia is hyperferritinemia without iron overload.
4. The method of claim 1 , wherein the one or more odd chain fatty acids is heptadecanoic acid.
5. The method of claim 1 , wherein the pharmaceutical composition is substantially free from even chain fatty acids.
6. The method of claim 1 , wherein the pharmaceutical composition comprises a plurality of odd chain fatty acids.
7. The method of claim 1 , wherein the pharmaceutical composition is in a unit dosage form and is configured for administration of from 2.5 mg to 11 mg, per 1 kg of body weight, of the one or more odd chain fatty acids or pharmaceutically acceptable salts thereof.
8. The method of claim 1 , wherein the pharmaceutical composition is in a unit dosage form and is configured for administration once per day.
9. The method of claim 1 , wherein the pharmaceutical composition is in a unit dosage form and comprises from 0.01 mg to 10000 mg of the one or more odd chain fatty acids or pharmaceutically acceptable salts thereof.
10. The method of claim 1 , wherein a serum concentration or a red blood cell membrane concentration of the one or more odd chain fatty acids is increased by at least about 0.01×10 −4 M above a pretreatment value.